Validity of chemotherapy information derived from routinely collected healthcare data: A national cohort study of colon cancer patients.

Published on Jul 2, 2021in Cancer Epidemiology2.984
· DOI :10.1016/J.CANEP.2021.101971
Michael Braun9
Estimated H-index: 9
Sources
Abstract
Abstract null null Background null We used a structured approach to validate chemotherapy information derived from a national routinely collected chemotherapy dataset and from national administrative hospital data. null null null Methods null 10,280 patients who had surgical resection with stage III colon cancer were included. First, we compared information derived from the national chemotherapy dataset (SACT) and from the administrative hospital dataset (HES) in the English NHS with respect to receipt of adjuvant chemotherapy (ACT). Second, we compared regimen and number of cycles in linked patient-level records. Third, we carried out a sensitivity analysis to establish to what extent the impact of ACT receipt differed according to data source. null null null Results null 6,012 patients (58 %) received ACT according to either dataset. Of these patients, 3,460 (58 %) had ACT records in both datasets, 1,649 (27 %) in SACT alone, and 903 (15 %) in HES alone. Of the 3,460 patients with records in both datasets, 3,320 (96 %) had matching regimens. There was good agreement on cycle number with similar proportions of patients recorded with a single cycle (6 % in SACT vs. 7 % in HES) and slightly fewer patients recorded with more than 8 cycles in SACT (32 % in SACT vs. 35 % in HES). 3-year cancer-specific mortality was similar for patients receiving ACT, regardless of whether a patient received ACT according to SACT alone (16.6 %), according to HES alone (16.8 %), or according to either SACT or HES (17.1 %). null null null Conclusion null Routinely collected national chemotherapy data and administrative hospital data are highly accurate in recording regimen and number of chemotherapy cycles. However, chemotherapy information should ideally be captured from both datasets to avoid under-capture, particularly of oral chemotherapy from administrative hospital data, and to minimise bias.
References24
Newest
#1Chloe J Bright (PHE: Public Health England)H-Index: 10
#2Sarah Lawton (PHE: Public Health England)H-Index: 6
Last. Rebecca Smittenaar (PHE: Public Health England)H-Index: 4
view all 11 authors...
Source
#1Laura McDonald (BMS: Bristol-Myers Squibb)H-Index: 8
#2Cormac J SammonH-Index: 7
Last. Sreeram V Ramagopalan (BMS: Bristol-Myers Squibb)H-Index: 8
view all 7 authors...
Aim: We assessed the extent to which chemotherapy cycles recorded in Hospital Episode Statistics (HES) Admitted Patient Care (APC) were captured in National Cancer Registration & Analysis Service Systemic Anti-Cancer Therapy (SACT) for a cohort of lung cancer patients. Methods: All chemotherapy cycles recorded for linkage eligible lung cancer patients with a National Cancer Registration & Analysis Service diagnosis between 2012 and 2015 were identified in HES APC and SACT. Results: Among a popul...
Source
#1G. Jones (University of Nottingham)H-Index: 4
#2Tricia M. McKeever (University of Nottingham)H-Index: 53
Last. David R Baldwin (University of Nottingham)H-Index: 46
view all 5 authors...
Background Thirty-day mortality after treatment for lung cancer is a measure of unsuccessful outcome and where treatment should have been avoided. Guidelines recommend offering chemotherapy to individuals with small cell lung cancer (SCLC) who have poorer performance status (PS) because of its high initial response rate. However, this comes with an increased risk of toxicity and early death. We quantified real-world 30-day mortality in SCLC following chemotherapy, established the factors associa...
Source
#1Katherine E Henson (PHE: Public Health England)H-Index: 10
#2Anna Fry (PHE: Public Health England)H-Index: 1
Last. Sean McPhail (PHE: Public Health England)H-Index: 21
view all 6 authors...
Sociodemographic inequalities in cancer treatment have been generally described, but there is little evidence regarding patients with advanced cancer. Understanding variation in the management of these patients may provide insights into likely mechanisms leading to inequalities in survival. We identified 50,232 patients with stage IV lung, oesophageal, pancreatic and stomach cancer from the English national cancer registry. A generalised linear model with a Poisson error structure was used to ex...
Source
#1Tom Treasure (UCL: University College London)H-Index: 72
#2Johanna J.M. Takkenberg (EUR: Erasmus University Rotterdam)H-Index: 60
Source
#1Masoud BabaeiH-Index: 15
#2Yesilda Balavarca (DKFZ: German Cancer Research Center)H-Index: 15
Last. Hermann Brenner (DKFZ: German Cancer Research Center)H-Index: 167
view all 12 authors...
The advantage of adjuvant chemotherapy (ACT) for treating Stage III colon cancer patients is well established and widely accepted. However, many patients with Stage III colon cancer do not receive ACT. Moreover, there are controversies around the effectiveness of ACT for Stage II patients. We investigated the administration of ACT and its association with overall survival in resected Stage II (overall and stratified by low-/high-risk) and Stage III colon cancer patients in three European countri...
Source
#1Axel Grothey (Mayo Clinic)H-Index: 87
#2Alberto SobreroH-Index: 64
Last. Roberto LabiancaH-Index: 72
view all 23 authors...
Abstract Background Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures. Methods We performed a prospective, preplanned, pooled analysis of six randomized, phase 3 trials that were conducted concurrently to evaluate the noninferiority o...
Source
#1Ryan Pathak (University of Manchester)H-Index: 2
#2M. Wallington (PHE: Public Health England)H-Index: 2
Last. Mark P SaundersH-Index: 28
view all 10 authors...
Abstract We audited the accuracy of the Systemic Anti-Cancer Therapy dataset as a resource for rapid analysis of outcomes for patients, in this example, receiving Cancer Drug Fund funded monoclonal antibodies to treat metastatic colorectal cancer. We concluded that the Systemic Anti-Cancer Therapy dataset is a potentially valuable resource for rapidly determining survival outcome for patients treated with chemotherapy.
Source
#1Sahar Mokhles (Erasmus University Medical Center)H-Index: 8
#2Johanna J.M. Takkenberg (Erasmus University Medical Center)H-Index: 60
Last. Tom Treasure (UCL: University College London)H-Index: 72
view all 3 authors...
Good clinical practice is an amalgamation of personalized medicine with evidence-based medicine in the best interests of patient. Hence, our title uses Boolean operators to indicate that it is [AND] not [OR]. This is the syntax of formal searching for systematic reviews, ensuring that all the evidence is found. Comprehensive evidence-based guidance can thus be formulated. Many residents and fellows around the world, and their chiefs, are now exposed to consensus documents, white papers, levels o...
Source
#1M. Wallington (PHE: Public Health England)H-Index: 2
#2Emma B SaxonH-Index: 1
Last. David DodwellH-Index: 35
view all 14 authors...
Summary Background 30-day mortality might be a useful indicator of avoidable harm to patients from systemic anticancer treatments, but data for this indicator are limited. The Systemic Anti-Cancer Therapy (SACT) dataset collated by Public Health England allows the assessment of factors affecting 30-day mortality in a national patient population. The aim of this first study based on the SACT dataset was to establish national 30-day mortality benchmarks for breast and lung cancer patients receivin...
Source
Cited By1
Newest
#1Jemma Boyle (Lond: University of London)H-Index: 2
#2Angela Kuryba (RCS: Royal College of Surgeons of England)H-Index: 9
Last. Ajay Aggarwal (Guy's and St Thomas' NHS Foundation Trust)H-Index: 18
view all 8 authors...
The impact of cycle completion rates of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer in real-world practice is unknown. We assessed its impact, and that of treatment modification, on 3-year cancer-specific mortality. Four thousand one hundred and forty-seven patients with pathological stage III colon cancer undergoing major resection from 2014 to 2017 in the English National Health Service were included. Chemotherapy data came from linked national administrative datasets. C...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.